本帖最后由 老马 于 2012-1-13 21:20 编辑
, ^% _' A O2 r5 G E& ~ t; H& s- c& M( {: F& l% Z
爱必妥和阿瓦斯丁的比较
, z% C ]5 f' x# z1 C
1 j% t" L7 H1 i
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
4 r3 x, X/ W9 _, v: O0 h' W8 ?
% |' r: [! ]4 w c9 U7 ?
" R0 j- @. H; O: |( I0 L, {# Xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 F8 G2 L$ \: a- @2 T& d0 R==================================================3 g' y8 `) n& k8 D* w# R/ c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& I! t; q0 N! R& P% A' u
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- c, b% T: I1 b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! W3 E, q0 Q' N/ o/ C4 @
|